Equities research analysts expect that Evolent Health Inc (NYSE:EVH) will report earnings of ($0.04) per share for the current fiscal quarter, Zacks Investment Research reports. Nine analysts have made estimates for Evolent Health’s earnings, with estimates ranging from ($0.07) to ($0.03). Evolent Health posted earnings of ($0.18) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 77.8%. The company is scheduled to announce its next quarterly earnings results on Tuesday, February 27th.
On average, analysts expect that Evolent Health will report full year earnings of ($0.36) per share for the current financial year, with EPS estimates ranging from ($0.40) to ($0.33). For the next fiscal year, analysts anticipate that the business will post earnings of ($0.06) per share, with EPS estimates ranging from ($0.13) to $0.03. Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that that provide coverage for Evolent Health.
Evolent Health (NYSE:EVH) last released its quarterly earnings data on Thursday, November 2nd. The technology company reported ($0.04) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.08) by $0.04. Evolent Health had a negative net margin of 15.86% and a negative return on equity of 5.05%. The firm had revenue of $107.90 million for the quarter, compared to the consensus estimate of $104.49 million. During the same period in the previous year, the company earned ($0.26) earnings per share. The company’s quarterly revenue was up 79.2% on a year-over-year basis.
Hedge funds have recently added to or reduced their stakes in the stock. FMR LLC lifted its position in Evolent Health by 117.7% during the second quarter. FMR LLC now owns 9,864,775 shares of the technology company’s stock worth $250,073,000 after purchasing an additional 5,333,252 shares during the period. JPMorgan Chase & Co. lifted its position in Evolent Health by 37.3% during the third quarter. JPMorgan Chase & Co. now owns 7,465,019 shares of the technology company’s stock worth $136,236,000 after purchasing an additional 2,026,893 shares during the period. Vanguard Group Inc. lifted its position in Evolent Health by 48.9% during the second quarter. Vanguard Group Inc. now owns 3,769,869 shares of the technology company’s stock worth $95,566,000 after purchasing an additional 1,237,941 shares during the period. Blair William & Co. IL lifted its position in Evolent Health by 31.4% during the second quarter. Blair William & Co. IL now owns 2,185,695 shares of the technology company’s stock worth $55,407,000 after purchasing an additional 522,874 shares during the period. Finally, TimesSquare Capital Management LLC lifted its position in Evolent Health by 5.7% during the third quarter. TimesSquare Capital Management LLC now owns 1,592,300 shares of the technology company’s stock worth $28,343,000 after purchasing an additional 86,300 shares during the period. Institutional investors and hedge funds own 95.38% of the company’s stock.
Evolent Health (NYSE:EVH) opened at $12.90 on Tuesday. Evolent Health has a fifty-two week low of $10.30 and a fifty-two week high of $27.50. The company has a debt-to-equity ratio of 0.11, a quick ratio of 3.34 and a current ratio of 3.34.
About Evolent Health
Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Evolent Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc and related companies with MarketBeat.com's FREE daily email newsletter.